Press Releases Altamira Therapeutics Nasdaq

Equities

CYTO

BMG0360L2099

Market Closed - Nasdaq Other stock markets 02:00:01 15/05/2024 am IST			5-day change	1st Jan Change
1.44 ^USD	0.00%		-8.86%	-58.62%

01/05	Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	CI
24/04	Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	01/05	AQ
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	24/04	AQ
Altamira Therapeutics : Notice of the Annual General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on May 16, 2024 - Form 6-K	17/04	PU
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results	10/04	AQ
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024	04/04	AQ
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	25/03	AQ
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	07/02	AQ
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	24/01	AQ
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit	08/01	AQ
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement	29/12	AQ
Altamira Therapeutics : Corporate Presentation Winter 2023	20/12	PU
Altamira Therapeutics : Reverse Share Split - Form 6-K	11/12	PU
Altamira Therapeutics Provides Investor and Business Update	11/12	AQ
Altamira Therapeutics : Warrant Inducement Agreement - Form 6-K	08/12	PU
Altamira Therapeutics to Host Investor & Business Update Call on December 11th	05/12	AQ
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement	29/11	AQ
Altamira Therapeutics : Compliance with Continued Listing Rule - Form 6-K	23/11	PU
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business	17/11	AQ
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine	10/11	AQ
Altamira Therapeutics : Notice of the Special General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on October 31, 2023 - Form 6-K	04/23/04	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Altamira Therapeutics Nasdaq

Equities

CYTO

BMG0360L2099

Press Releases

Filters